Evidence map›Paper›PMID 27073407›Full record

ReviewNutrition & metabolism2016

Does larch arabinogalactan enhance immune function? A review of mechanistic and clinical trials.

Carine Dion, Eric Chappuis, Christophe Ripoll

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Nutrition & metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04005924 (An Acute, Randomized, Double-blind, Controlled, Crossover Study to Investigate the Effect of an Arabinogalactan Product on Glucose and Insulin Response in Adults), which is not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
18.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04005924 nacompletednot on this mapstarted 2019, after this paper: background citation

An Acute, Randomized, Double-blind, Controlled, Crossover Study to Investigate the Effect of an Arabinogalactan Product on Glucose and Insulin Response in Adults

TypeinterventionalSponsorBiofortis, Merieux NutriSciencesRan2019 to 2019Enrolled20ConditionsPostprandial Blood GlucoseArmsarabinogalactan
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 97 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Tissue Lipid Profiles of Rainbow Trout,Animals : an open access journal from MDPI · 2023
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Arabinogalactan enhancesFrontiers in immunology · 2022
    Article
  18. Review
  19. Review
  20. Effects ofFrontiers in microbiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Carine DionNaturalpha SAS, Parc Eurasanté, 885 avenue Eugène Avinée, 59120 Loos, France.
Eric ChappuisNaturalpha SAS, Parc Eurasanté, 885 avenue Eugène Avinée, 59120 Loos, France.
Christophe RipollNaturalpha SAS, Parc Eurasanté, 885 avenue Eugène Avinée, 59120 Loos, France.
Eurasanté · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The common cold is a viral infection with important economic burdens in Western countries. The research and development of nutritional solutions to reduce the incidence and severity of colds today is a major focus of interest, and larch arabinogalactan seems to be a promising supportive agent. Arabinogalactan has been consumed by humans for thousands of years and is found in a variety of common vegetables as well as in medicinal herbs. The major commercial sources of this long, densely branched, high-molecular-weight polysaccharide are North American larch trees. The aim of this article is to review the immunomodulatory effects of larch arabinogalactan derived from Larix laricina and Larix occidentalis (North American Larix species) and more specifically its role in the resistance to common cold infections. In cell and animal models, larch arabinogalactan is capable of enhancing natural killer cells and macrophages as well as the secretion of pro-inflammatory cytokines. In humans a clinical study demonstrated that larch arabinogalactan increased the body's potential to defend against common cold infection. Larch arabinogalactan decreased the incidence of cold episodes by 23 %. Improvements of serum antigen-specific IgG and IgE response to Streptococcus pneumoniae and tetanus vaccination suggesting a B cell dependent mechanism have been reported in vaccination studies with larch arabinogalactan, while the absence of response following influenza vaccination suggests the involvement of a T cell dependent mechanism. These observations suggest a role for larch arabinogalactan in the improvement of cold infections, although the mode of action remains to be further explored. Different hypotheses can be envisaged as larch arabinogalactan can possibly act indirectly through microbiota-dependent mechanisms and/or have a direct effect on the immune system via the gut-associated lymphoid tissue (GALT).

Indexed as

Common cold infectionsDietary fibersImmune systemLarch arabinogalactanLarixPolysaccharidesResistAid®SCFAVaccine

Identifiers

PMID27073407
PMCPMC4828828
OpenAlexW2336520496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.